Author

Nadezhda Rotankova

Primary ORCID profile (0009-0001-7066-3235 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Nadezhda RotankovaiD1 paper · ETH Zurich

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

André RosaiD· 1 shared Carlos‐Filipe PereiraiD· 1 shared Charlotte VeseriD· 1 shared David AskmyriD· 1 shared Emilie RenaudiD· 1 shared Ervin AsciciD· 1 shared Fábio Alexandre RosaiD· 1 shared Ilia KurochkiniD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

André RosaORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A cancer immunotherapy modality based on dendritic cell reprogramming in vivo

Ervin Ascic, Malavika Sreekumar Nair, André Rosa, Ilia Kurochkin, Olga Zimmermannová, Nadezhda Rotankova, Charlotte Veser, Tommaso Ballocci, Tiffany Schärer, Xiaoli Huang, Emilie Renaud, Marta Velasco Santiago, Özcan Met, David Askmyr, Malin Lindstedt, , Carlos‐Filipe Pereira

This study reprograms tumor cells in vivo to function as dendritic cells, leading to tumor regression and long-term immunity in mouse models.

Science · Aug 1, 2024Peer-reviewedImmunology